Royal Securities

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry. Founded in 1996, the company specializes in acquiring royalty interests in marketed and late-stage development drugs from academic institutions, research hospitals, and biotechnology companies. Its extensive portfolio includes royalties on blockbuster therapies such as Vertex's cystic fibrosis franchise, AbbVie's Imbruvica, and Biogen's Tysabri. Royalty Pharma provides liquidity to innovators while offering investors diversified exposure to the pharmaceutical industry's most successful products. The company operates as a specialized capital provider rather than a traditional drug developer, focusing on high-value assets with long-term commercial potential.